Union of Swiss Societies of Experimental Biology Abstracts of the 18 Th Annual Meeting

Total Page:16

File Type:pdf, Size:1020Kb

Union of Swiss Societies of Experimental Biology Abstracts of the 18 Th Annual Meeting Union of Swiss Societies of Experimental Biology Abstracts of the 18 th Annual Meeting Union des Soci&~s Suisses de Biologie Exp6rimentale Comptes rendus de la 18 e Rdunion annuelle Union Schweizerischer Gesellschaften ffir Experimentelle Biologie Berichte der 18. Jahresversammlung Basel, 20/21 March 1986 Unterstfitzt durch die Schweizerische Naturforschende Gesellschaft fiber die Schweizerische Kommission ffir Experimentelle Biologie 630 Experientia 42 (1986), Birkh/iuser Verlag, CH-4010 Basel/Switzerland Symposium I: Neuronal regeneration and transplantation Influence of adenohypophyseal tissue on the development of the rat fascia dentata in vitro Precursor cells of dorsal root ganglia in chick embryo: B. H. G~ihwiler and J. Zimmer , Preclinical Research, Sandoz Ltd, differentiation into neurons in culture CH-4002 Basel, and Institute of Anatomy B, University of Aar- hus, DK-8000 Aarhus C I. Barakat and B. Droz, Institut d'Histologie et d'Embryologie, 9, rue du Bugnon, CH-IO05 Lausanne In hippocampal slice cultures, the mossy fibers from the dentate granule cells were previously shown by Timm-stainingto retain Dissociated DRG cells from 10-day-old chick embryos were their normal connections to CA4 and CA3 pyramidal cells. cultured into two types of culture: neuron-enriched culture and During co-cultivation with an adenohypophyseal explant, the mixed DRG cell culture. In neuron-enriched cultures, the num- infrapyramidal blade of the fascia dentata largely disappeared as ber of neurons decreases with time, while in mixed DRG cell a cell layer; granule cell-like neurons would migrate toward the culture the number of neurons increases with time until 7 days of hypophyseal explant, whilst their axons still functionally inner- culture. The incorporation of 3H-thymidine into DRG ganglion vated CA3 pyramidal cells. Axon collaterals projected in the cells could not account for the increased number of cultured opposite direction and presumably terminated on dendrites, neurons. thus giving rise to the intense black labeling which was observed Microphotographs of the same area, taken every 60 rain, showed in Timm-stained preparations as a bridge connecting the two that small and flat cells can differentiate into neurons which were explants. identified by their morphological characteristic and by specific The morphological alterations induced in the fascia dentata by neuronal markers such as specific neuronal enolase and D2/N- co-cultured adenohypophysis were tissue-specific since co-cul- CAM. It is concluded that embryonic DRG in chicken contain tured neurohypophysis, pineal gland and cerebellum failed to progenitor cells which are able to differentiate into sensory neu- produce similar effects. These results suggest that cultured ade- rons in culture. nohypophyseal tissue is capable of releasing yet unidentified factors which apparently enhance neuronal migration. Concanavalin A and extracellular matrix mediate rapid outgrowth of leech neurons in saline M. Chiquet and S. Acklin, Biozentrum der Universitgit Basel, Evidence for sprouting of hippocampal cholinergic and Klingelbergstrasse 70, CH-4056 Basel aminergic fibers following partial deafferentation in rats The outgrowth of neurites in culture by single identified neurons U. Gasser and A. Dravid, Preclinical Research, Sandoz Ltd, of the leech is markedly influenced by the substrate. On cell-free CH-4002 Basel extracellular matrix, extensive sprouting occurs within a few Cholinergic enzyme activities and high affinity uptake of 3H- hours. Another substrate promoting sprouting is the plant lec- noradrenaline and 3H-serotonin were measured in septotem- tin, concanavalinA (con A). Neurons had to be attached directly poral regions of the hippocampus following partial or complete to substrate-bound con A or extracellular matrix to grow neu- fornix-fimbria transection. Subsequent to an initial reduction rites and did so in physiological saline or medium without any reflecting terminal degeneration, a significant increase in these macromolecular substances or other cells present. Sprouting on parameters was observed. Recovery of these terminal-specific con A was inhibited by the con A-specific hapten sugar ~-methyl markers most likely represents synapse replacement following mannoside. These results show that the substrate can mediate sprouting of the remaining undamaged fibers. The extent of the outgrowth of cultured leech neurons; soluble growth factors recovery seems to depend on the degree of deafferentation and are not required. However, sprouting depends not simply on was different for each transmitter system. Substantial recovery attachment to substrate but, critically, on its molecular composi- occurred within 8 weeks after partial lesions whereas after exten- tion, since other adhesive substrates did not promote sprouting. sive deafferentation the magnitude of recovery was lower and was apparent only after longer survival times. Acute facial palsy: a virological and histopathological study M. Engels, H. Felix and E. Loepfe, Institute of Virology, Univer- Evidence for the role of nerve growth factor (NGF) in sity of Ziirich, ENT-Department, University Hospital, CH-8001 central cholinergic neurons in rats Ziirieh U. Gasser, G. Weskamp, U. Otten and A. Dravid, Preclinical Virological and/or histopathological investigations have been Research, Sandoz Ltd, and Dept Pharmacology, Biocenter of the performed on 21 specimens removed from the greater petrosal University of Basel, CH-4056 Basel nerve in the course of surgical decompression of the facial nerve Cholinergie enzyme activities and NGF levels in the septum and (performed by Prof. U. Fisch) within 14 days from onset of Bell's hippocampus were measured at various times after complete Palsy. Nine specimens were examined for virus infection by a bilateral transection of the dorsal septohippocampal pathway. modified coculture method. The specimens were maintained in Within 3-7 days after transection, there was a maximal increase cell culture medium for 28 days at 37~ Vero cells were inocu- in NGF content of about 50 % in the hippocampus and 290 % in lated every day with supernatant. Infected cell supernatants un- septum followed, in both regions, by a decline to control values derwent two blind passages and, additionally, were inoculated on postlesion day 14. Cholinergic enzyme activities indicated an into the allantois and amnion of embryonated eggs. The fluids almost complete terminal degeneration in the hippocampus. In were tested for hemagglutinins. In no case any virus could be the septum, however, an initial decrease of 15 % was followed by isolated. The main morphological changes observed were nerve gradual increase to about 20% over the control levels after fiber degeneration and demyelination, and in 8 of 15 specimens longer survival time. Fornix-fimbria lesion and the resulting endoneurial fibrosis was present, In 10 cases a minimal infiltra- destruction of the cholinergic system, appears to induce en- tion of lymphocytes was observed. The etiological relationship hancement of NGF in the hippocampus and septum. These between the virological and histopathological findings in acute findings thus support the role of NGF in central cholinergic facial palsy is discussed. neurons. Experientia 42 (1986), Birkh/iuser Verlag, CH~4010 Basel/Switzerland 631 Isolation of eDNA clones from C6 rat glioma RNA cod- tube technique. The metabolism of choline and the synthesis of ing for a glia-derived neurite-promoting factor (GdNPF) acetylcholine (ACh) were investigated, in living cultures, in pres- ence of different radiolabeled precursors, and at various precur- S. Gloor, J. Giinther and D. Monard, Friedrich-Miescher-Institut, sor concentrations, and compared with the metabolism in stri- P.O. Box 2543, CH-4002 Basel atal slices of adult rat brain. Acute slice preparations of the GdNPF is a 43 kD glycoprotein which promotes neurite exten- newborn septal area and mature cultures showed different pat- sion in neuroblastoma cells and strongly inhibits serine proteases terns of choline metabolism, indicating in vitro maturation or (Giinther, J., Nick, H., and Monard, D., EMBO J. 4 (1985) regeneration of cholinergic neurons and nerve terminals. Mature 1963). RNA from C6 glioma cells was isolated, translated both cultures showed many biochemical characteristics of the tissue in in vivo and in vitro and the protein immunoprecipitated with situ, such as enhancement of ACh synthesis by depolarization polyclonal anti-GdNPF antibodies. Sucrose gradient enriched and de novo choline formation. In absence of extracellular poly(A)+ RNA was used for eDNA synthesis. The cDNA li- choline, ACh was synthesized from choline derived from the brary obtained was screened by the method of hybrid selected methylation of phosphatidylethanolamine. translation. A clone with a 800 bp insert coding for GdNPF was used for the estimation of the amount of GdNPF mRNA at different stages of rat brain development. Structural and functional aspects of glia-derived neurite promoting factor (NPF) H. Nick, J. Giinther and D. Monard, Friedrich-Miescher-Institut, Non-neuronal cells influence the cholinergic properties of P.O. Box 2543, CH-4002 Basel cultured human spinal cord neurons NPF is a protein with a single polypeptide chain of mol.wt A. C. Kato, L. Bierman and L. Erkman, Department of Pharma- 43,000 (SDS-PAGE). It promotes the formation of neurites in cology, CMU, CH-1211 Gen~ve 4 NB2a neuroblastoma cells. NPF is a strong inhibitor of serin Dissociated monolayer cultures
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Modulation of Primary Amine Oxidase by Phytochemicals
    Technological University Dublin ARROW@TU Dublin Masters Science 2018-6 Modulation of Primary Amine Oxidase by Phytochemicals Padraig Shanahan Dublin Institute of Technology, [email protected] Follow this and additional works at: https://arrow.tudublin.ie/scienmas Part of the Medicine and Health Sciences Commons Recommended Citation Shanahan, P. (2018) Modulation of Primary Amine Oxidase by Phytochemicals, MA, Technological University Dublin. doi.org/10.21427/m580-nk39 This Theses, Masters is brought to you for free and open access by the Science at ARROW@TU Dublin. It has been accepted for inclusion in Masters by an authorized administrator of ARROW@TU Dublin. For more information, please contact [email protected], [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License Modulation of Primary Amine Oxidase by Phytochemicals. Padraig Shanahan B.Sc. Department of Food Science & Environmental Health Dublin Institute of Technology A thesis submitted to Dublin Institute of Technology for the award of Master of Philosophy Research Supervisors: Professor Gary T.M. Henehan Dr. Barry Ryan Dr. Gemma K Kinsella June 2018 Declaration I certify that this thesis which I now submit for examination for the award of M.Phil, is entirely my own work and has not been taken from the work of others, save and to the extent that such work has been cited and acknowledged within the text of my work. This thesis was prepared according to the regulations for graduate study by research of the Dublin Institute of Technology and has not been submitted in whole or in part for another award in any other third level institution.
    [Show full text]
  • Drugs Affecting Central Nervous System
    Drugs Affecting Central Nervous System Psychotherapeutic drugs Antidepressants Vincent van Gogh, 25.07.1890 Depression Depression is an affective illness, whose pathomechanism is not completely known. It can have different degrees of intensity. Physiological depression may appear after a loss of a loved one, a change of the environment, a failure at work or school and many others. It is the mildest form of depression and it usually disappears spontaneously. Neurotic depression is caused by an emotional problem of which a person is not aware. In this type of depression psychotherapy is recommended, but sometimes treatment using antidepressants is effective. 2 Depression Psychotic depression, which is the most serious form of depression, is usually caused by pathologic changes and requires hospital treatment with psychotropic drugs. Melancholia is the most serious form of endogenic psychotic depression. This depression type often affects pedantic people who pay too much attention to order and who are extremely conscientious. They suffer from it because of their sudden feeling of the pointlessness of life. Bipolar disorder, also called manic-depressive psychosis, is characterized by alternating periods of deep depression and decreased activity and periods of euphoria accompanied by increased activity. The manic phase of a euphoric mood can last for only several days, but it sometimes lasts for weeks, months and even up to two years. Periods of remission occur between the two phases. The frequency of changes is unpredictable and in some individuals changes can occur even in daily cycles. 3 Depression Depressions are the most common diseases in psychiatry and affect about 10- 12% per cent of the world population.
    [Show full text]
  • Enzyme Systems That Metabolise Drugs and Other Xenobiotics
    Enzyme Systems that Metabolise Drugs and Other Xenobiotics. Edited by Costas Ioannides Copyright # 2001 John Wiley & Sons Ltd ISBNs: 0-471-894-66-4 %Hardback); 0-470-84630-5 %Electronic) Enzyme Systems that Metabolise Drugs and Other Xenobiotics Current Toxicology Series Series Editors Diana Anderson Michael D Waters Timothy C Marrs Department of Consultant Food Standards Agency Biomedical Sciences Chapel Hill London, UK University of Bradford, UK NC, USA Toxicology is now considered to be a topic worthy of study and research in its own right, having originally arisen as a subsection of pharmacology. This rapid growth in the signi®cance of toxicology necessitates specialised yet comprehensive information that is easily accessible both to professionals and to the increasing number of students with an interest in the subject area. Comprising professional and reference books, primarily aimed at an academic/ industrial/professional audience, the Current Toxicology Series will cover a wide variety of `core' toxicology topics, thus building into a comprehensive range of books suitable for use both as an updating tool and as a reference source. Published titles Nutrition and Chemical Toxicity Edited by C Ioannides 10 471 974536) Toxicology of Contact Dermatitis: Allergy, Irritancy and Urticaria D Basketter, F Gerberick, I Kimber and C Willis 10 471 97201 0) Food Borne Carcinogens: Heterocyclic Amines Edited by M. Nagao and T. Sugimura 10 471 98399 3) Enzyme Systems that Metabolise Drugs and Other Xenobiotics Edited by C Ioannides 10 471 89466 4) Enzyme Systems that Metabolise Drugs and Other Xenobiotics Edited by Costas Ioannides School of Biomedical and Life Sciences, University of Surrey, Guildford, UK Copyright # 2002 by John Wiley & Sons, Ltd., Baf®ns Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International 144) 1243 779777 e-mail 1for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved.
    [Show full text]
  • Wo 2009/100255 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 13 August 2009 (13.08.2009) WO 2009/100255 A2 (51) International Patent Classification: (74) Agent: WALLEN, John, W., Ill; 10975 North Torrey C07K 14/705 (2006.01) Pines Road, Suite 100, La JoUa, CA 92037 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2009/033277 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, 5 February 2009 (05.02.2009) EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, (30) Priority Data: NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, 61/027,4 14 8 February 2008 (08.02.2008) US SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): AM- BRX, INC. [US/US]; 10975 North Torrey Pines Road, (84) Designated States (unless otherwise indicated, for every Suite 100, La JoUa, CA 92037 (US). kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (72) Inventors; and ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (75) Inventors/Applicants (for US only): KRAYNOV, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Vadim [US/US]; 5457 White Oak Lane, San Diego, CA ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 92130 (US).
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]